

May, 2009

Columbus CCOP
1335 Dublin Road, Suite
124-A
Columbus, OH 43215

Phone: 614-488-2118
Fax: 614-488-2647
www.columbusccop.org

CCOP NEWS




A Community of Caring in Cancer Research

Columbus Community Clinical Oncology Program

MARK YOUR CALENDAR!

Join your colleagues to hear the latest information in oncology presented by *eight nationally recognized speakers*. Registration brochures have been mailed and are available at www.columbusccop.org.



Gynecologic Malignancies
Dr. Maurie Markman
MD Anderson Cancer Center

Lung Cancer
Dr. Mark Socinski
University of North Carolina

Brain Cancer
Dr. Mark Gilbert
MD Anderson Cancer Center

GU Cancers
Dr. Derek Raghavan
Cleveland Clinic

Breast Cancer
Dr. Claudine Isaacs
Georgetown University

GI Cancers
Dr. Richard Goldberg
University of North Carolina

Lymphoma
Dr. Richard Fisher
James P Wilmot Cancer Center

Cancer Control
Dr. Charles Loprinzi
Mayo Clinic

MAY IS MELANOMA/SKIN CANCER DETECTION & PREVENTION MONTH

Warmer weather has arrived and people will be spending more time in the sun. May is a month to encourage and remind people to take preventive measures to protect themselves. According to the American Cancer Society, there are more than 1 million cases of skin cancer diagnosed each year in the United States, which is more than cancers of the prostate, breast, lung, colon, uterus, ovaries and pancreas combined. Most skin cancers are caused by too much exposure to ultraviolet (UV) rays from the sun and manmade sources, such as tanning beds. Melanoma, the most serious form of skin cancer, accounts for about four percent of skin cancer cases, but causes about 79 percent of skin cancer deaths.



You can visit the following web sites to learn more:

<http://www.cancer.gov/cancertopics/types/skin>

<http://www.cancer.org>

<http://www.upmccancercenters.com/awareness/5melanoma/>

OUR MISSION: The Columbus Community Clinical Oncology Program (Columbus CCOP) strives to deliver state-of-the-art cancer care to patients in their communities through clinical trials. This allows individuals to remain in their own neighborhoods while receiving the latest and best in cancer screenings, diagnostic care and treatment plans.

Please send newsletter comments to steveo@columbusccop.org



DR. KUEBLER'S CCOP UPDATES

KUEBLER'S



I hope all of you are as busy as we are at the Columbus CCOP central office. Accruals have picked up, which is good news! The CCOP central office staff is pleased to be busy assisting you in placing your patients on appropriate trials.

We are actively preparing our competitive grant submission due later this summer. You may be asked to update your curriculum vitae or sign off on some forms. As always, I know we can depend on your help and support.

I would like to say a few words about trials with negative results. Recently the Data Monitoring Committees at NSABP and ECOG released results for 2 major phase III trials. In NSABP-C08, the efficacy of adding Bevacizumab to standard adjuvant chemotherapy for patients with stage II or III resected colon cancer did not meet the primary endpoint of reducing risk for cancer recurrence. In the ECOG E2603 study, the addition of sorafenib to chemotherapy for locally advanced and metastatic melanoma reached futility boundaries which means a negative result. While we would like all of our trials to be positive, we should not be discouraged by negative results. Both studies provided important information and spare patients from possible toxic and costly therapies. Any clinical trial that is well designed and executed provides useful scientific information. We must now begin to acknowledge that there are limits to the effectiveness of our present biologic agents.

As always, good data opens up more questions which will result in the design of more clinical studies to answer these queries. So hang in there! As the fight song of my Notre Dame alma mater says: we "will win over all". (ok ... not over Ohio State ... yet!!)

We are getting ready for our annual ASCO Review. This is the 10th straight year for this event! Our speakers consist of top experts in each disease area discussed. I urge you to consult the schedule on the 2009 ASCO registration brochure and attend as many of the presentations as you can. Be sure and register soon! Brochures have been mailed and you should have received yours by now! If you did not, you can get one at www.columbusccop.org, or call Steve at 614-488-3321. He will make sure you get one immediately. I hope to see all of you there on June 18th.



COLUMBUS CCOP DONATIONS

The Columbus Community Clinical Oncology Program's mission is to deliver state-of-the-art cancer care to patients in their communities through clinical trials. We are grateful for donations from individuals. The Columbus CCOP is a 501 (c) (3) organization and your contribution is tax deductible.

You can help support the Columbus CCOP by visiting our web site at:

<http://www.columbusccop.org/news/nletters/CCOP%20Donation%20Form.pdf>.

You can also make a credit card donation through the Columbus Foundation at:

www.columbusfoundation.org.



MARK YOUR CALENDAR

May 29, 2009—June 2, 2009: **ASCO Annual '09 Meeting**, Orlando, Florida. The 2009 ASCO Annual Meeting will be a forum for cutting-edge scientific and educational developments in oncology with a focus on personalizing cancer care. Visit their website at <http://www.asco.org/ASCO/Meetings/ASCO+Annual+Meeting>



June 18, 2009: Don't miss the **Columbus CCOP 2009 ASCO Review** to be held at the Villa Milano, Columbus, Ohio. Our line up of expert speakers will present the latest developments in oncology. Registration forms have been mailed and are available on the Columbus CCOP website at www.columbusccop.org.



July 30, 2009: Dr. Zale Bernstein will give a presentation titled **A Clinical Perspective on the Treatment of Non Hodgkin's Lymphoma** at the Hyde Park Steakhouse, 569 N. High Street, Columbus, Ohio, on July 30th at 6:30 pm. Dr. Bernstein is Medical Director, Center for Cancer Care and Immuno Blood Conditions, State University of New York at Buffalo School of Medicine. This presentation is being provided by Cephalon, Inc. Registration information will be available soon.



2009 "MOMS – SCHEDULE A MAMMOGRAM" CAMPAIGN

Ohio Partners for Cancer Control (OPCC), a statewide coalition of cancer-related organizations working together to reduce the burden of cancer among Ohioans, has announced its 2009 "MOMS – *Schedule a Mammogram*" Campaign. The MOMS Campaign will be multi-faceted and will include legislative, physician outreach, and public awareness components. The campaign has been linked to Mother's Day, and the target audience will include legislators, women and their families, and the general public throughout the state of Ohio.



MOMS consists of 3 components:

The **legislative component** of MOMS kicked-off the campaign in downtown Columbus on Tuesday, May 5th at the Statehouse Atrium. The goal was to garner media attention and educate legislators about the importance of mammography screening. Event activities included a legislative reception, a keynote speaker, and mammography and breast health displays by member organizations.

The second component of MOMS is **physician outreach**. Primary care physicians and gynecologists throughout the state of Ohio have been sent information about the MOMS campaign and its mission. The package included a letter describing the MOMS campaign and physician's role in the campaign (encouraging women to get mammograms, etc.), a list of resources to help low socio-economic status (SES) women obtain mammograms and a fact sheet for Ohio containing the most recent data and statistics about breast cancer and mammography screening in Ohio.

The final component of the MOMS campaign is **public awareness**. Radio and TV Public Service Announcements (PSAs) were recorded and distributed throughout the state of Ohio for airing in the weeks prior to Mother's Day. PSAs provide information for interested individuals to call the Cancer Information Service of the National Cancer Institute (NCI) for more information about mammography screenings. Callers will be able to speak with a live Cancer Information Specialist who has the ability to refer them to mammography sites in their area, as well as free and low cost mammography resources and facilities.



I urge you to support this worthwhile effort by encouraging those special women you know to get a mammogram!

A handwritten signature in black ink, appearing to read "Reilly".



Please welcome Dr. Tejas Lodhawala to the Columbus CCOP. Dr. Lodhawala currently practices at Hematology Oncology Consultants, Inc. and Riverside Methodist Hospital.

NCI TRIAL NEWS

The Columbus CCOP has accrued about 51.7 **cancer control** credits this year. Columbus CCOP members are asked to continue their focus of screening new patients to determine if they are eligible for cancer control studies. Below is a list of cancer control trials currently available through the Columbus CCOP. As always ... thank you for your support!



ECOG E5597	Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage 1 Non-Small Cell Lung Cancer
HLMCC 0501	Stress Management Therapy for Patients Undergoing Chemotherapy. Open for Hispanic patients only.
NCCTG N07C2	The Use of Wisconsin Ginseng (panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
NCCTG N08C1	Paclitaxel-Associated Acute Pain Syndrome Natural History Study
SWOG S0424	Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
SWOG S0702	A prospective observational multicenter cohort study to assess the incidence of osteonecrosis of the jaw in patients with bone metastases starting zoledronic acid
URCC 07079	Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind, Placebo-Controlled Clinical Trial
URCC U1105	Prevention of Delayed Nausea - A Phase III Double-Blind Placebo-Controlled Clinical Trial
URCC U1701	Dyspnea in Cancer Patients

SWOG S0230: This trial has been open at the Columbus CCOP since July, 2008. Accrual has been low nationally. Everyone is asked to consider this trial for eligible patients. The objective of this phase II trial is to see if LHRH (Zoladex) given during chemotherapy will reduce premature ovarian failure afterwards in premenopausal women. They must be ER(-) and PR(-). If they have had their surgery prior to their chemotherapy, they must start treatment within 84 days, if the treatment will be given prior to surgery, no further chemotherapy must be planned for after surgery. The chemotherapy must be 3-8 months or cycles of an alkylating anthracycline-based or non-anthracycline based treatment. They may be on other treatment studies as long as the treatment meets the requirements of the protocol. They will be randomized to Zoladex plus chemotherapy or chemotherapy alone. If randomized to Zoladex it must be given one week prior to start of treatment then monthly.

Please remember to consider cancer control protocols found in the Columbus CCOP protocol book.

Protocol and consent forms can be found at www.columbusccop.org

